Jan-Anders Karlsson

Former Chief Executive Officer & Executive Director at Verona Pharma PLC

Jan-Anders Karlsson

Jan-Anders Karlsson

Former Chief Executive Officer & Executive Director at Verona Pharma PLC

Overview
Career Highlights

Verona Pharma PLC
S*BIO Pte Ltd.

RelSci Relationships

537

Number of Boards

2

Birthday

1955

Age

65

Relationships
RelSci Relationships are individuals Jan-Anders Karlsson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at ElevateBio LLC

Relationship likelihood: Strong

Chief Executive Officer at OM Pharma SA

Relationship likelihood: Strong

Head, Sackler Institute of Pulmonary Pharmacology at King's College London

Relationship likelihood: Strong

Former Chief Executive Officer & Director at C4X Discovery Ltd.

Relationship likelihood: Strong

Head-Copd Center at Sahlgrenska Universitetssjukhuset

Relationship likelihood: Strong

Executive Chairman at PolyTherics Ltd.

Relationship likelihood: Strong

Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Venture Partner at Vivo Capital LLC

Relationship likelihood: Strong

Partner & Portfolio Manager at Abingworth LLP

Relationship likelihood: Strong

General Counsel at Verona Pharma PLC

Relationship likelihood: Strong

Paths to Jan-Anders Karlsson
Potential Connections via
Relationship Science
You
Jan-Anders Karlsson
Former Chief Executive Officer & Executive Director at Verona Pharma PLC
Education

Uppsala Universty is a world class research and educational institution in Sweden.

Lund University is one of northern Europe's oldest and most prestigious universities.

Career History
Chief Executive Officer & Executive Director
2012 - 2020

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. It's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The firm develops RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.

Chief Executive Officer
2005 - Prior

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Executive Vice President-Global Research
1996 - Prior
Boards & Committees
Member, Executive Management Committee
Prior
Transactions
Details Hidden

Verona Pharma PLC raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jan-Anders Karlsson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jan-Anders Karlsson's profile does not indicate a business or promotional relationship of any kind between RelSci and Jan-Anders Karlsson.